Skip to Content

Conjupri FDA Approval History

Last updated by Judith Stewart, BPharm on July 27, 2020.

FDA Approved: Yes (First approved December 19, 2019)
Brand name: Conjupri
Generic name: levamlodipine maleate
Dosage form: Tablets
Company: CSPC Pharmaceutical Group Limited
Treatment for: High Blood Pressure

Conjupri (levamlodipine maleate) is a calcium channel blocker indicated for the treatment of hypertension.

Development Timeline for Conjupri

DateArticle
Dec 20, 2019Approval  FDA Approves Conjupri (levamlodipine maleate) for the Treatment of Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.